EcoDrugPlus

Melanocortin 1 Receptor

Ensembl ID : ENSOTSG00005017642
Gene Symbol: MC1R
1 Cross references
155 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSOTSG00005025064
Gene Symbol: MC3R
1 Cross references
133 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOTSG00005025153
Gene Symbol: MC4R
1 Cross references
24 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOTSG00005017881
Gene Symbol: MC4R
1 Cross references
76 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOTSG00005043868
Gene Symbol: MC4R
1 Cross references
76 Possible Orthologues:

Melanocortin Receptor 3-Like

Ensembl ID : ENSOTSG00005011044
Gene Symbol: LOC112215217
3 Cross references
133 Possible Orthologues:

Melanocortin Receptor 4-Like

Ensembl ID : ENSOTSG00005022159
Gene Symbol: LOC112226470
3 Cross references
24 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSOTSG00005014608
Gene Symbol: LOC112227760
2 Cross references
207 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSOTSG00005036980
Gene Symbol: LOC112215338
2 Cross references
207 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSOTSG00005046253
Gene Symbol: LOC112215338
2 Cross references
207 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSOTSG00005013888
Gene Symbol: LOC112227760
2 Cross references
207 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSOTSG00005041573
Gene Symbol: MTNR1A
1 Cross references
136 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).